Travere Therapeutics — Third Quarter 2026 Earnings Summary

Travere Therapeutics reported third-quarter 2026 U.S. net product sales of $220.2 million, driven by a 120% year-over-year increase in FILSPARI sales to $200.2 million. The company received 1,932 new patient start forms during the quarter and recognized a $113.1 million in-process research and development expense related to its civorebrutinib licensing agreement. Clinical updates include ongoing enrollment in the Phase 3 HARMONY study for pegtibatinase, with topline results expected in the second half of 2027, and a planned U.S. IND submission for civorebrutinib by year-end. The company reported a net loss of $52.3 million for the quarter, while maintaining $471.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.